Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

For Amylyx AMX0035 Panel Review, US FDA Relied Heavily on Temporary Voting Members

Apr 02 2022

• By Sue Sutter

FDA advisory committee member puzzle — • Source: Alamy

Related Content

Aduhelm Approval Firestorm Raises Question: What Are US FDA Advisory Committees For, Anyway?

Jun 11 2021

Biogen’s Aducanumab: Why Accelerated Approval Might, And Might Not, Be An Option For US FDA

Nov 13 2020

What Did US FDA Do Wrong In Its Review Of Aducanumab? AdCom Members Have A List

Nov 08 2020

Biogen’s Aducanumab Falls Hard At Panel Review, Leaving US FDA In A Tight Spot

Nov 08 2020

Aducanumab's Big Day Arrives, But How Much Will US FDA Panel Vote Matter?

Nov 05 2020

USA FDA Gives Biogen Big Hand In Effort To Get Its Alzheimer’s Treatment On The Market

Nov 05 2020

Amylyx’s ALS Drug Brings Questions On Efficacy Data Robustness To US FDA Panel

Mar 28 2022

One Difference Between Amylyx’s ALS Drug And Aduhelm: A Biomarker Endpoint

Mar 31 2022

Amylyx’s ALS Drug Should Wait For Phase III Results, US FDA Panel Says

Mar 31 2022

Related Companies

Amylyx Pharmaceuticals, Inc.

Biogen, Inc.

Eisai Co., Ltd.

AbbVie Inc.

Additional Topics

United States Advisory Committees Drug Review Rare Diseases Regulation Neurology BioPharmaceutical

More from US FDA Performance Tracker

More from Regulatory Trackers

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window